Reverse DCF
What growth does the market imply for AUROPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
13.9% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹1,467
Historical Growth
2.3%
FCF Yield
2.87%
Price / FCF
34.9x
Plain English
To justify today's price of ₹1467.00, AUROPHARMA.NS needs to grow its free cash flow at 13.9% per year for the next 10 years. That is 11.6% faster than its historical growth rate of 2.3%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 2.3% | ₹584 | -60.2% |
| Half implied | 7.0% | ₹842 | -42.6% |
| GDP rate | 10.0% | ₹1,071 | -27.0% |
| Implied | 13.9% | ₹1,467 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 2.3% growth, the model values AUROPHARMA at ₹584, below today's ₹1,467.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.